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Background 28 
IgA nephropathy (IgAN) is postulated to be associated with mucosal immune system 29 
dysfunction, manifesting as renal IgA deposition leading to impairment and end-stage renal 30 
disease (ESRD) in 20–40% of patients over 10–20 years. The NEFIGAN trial investigated a 31 
novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver drug 32 
to the distal ileum in IgAN patients. 33 
Methods 34 
Randomised, double-blinded, placebo-controlled trial: 6-month run-in, 9-month treatment, 35 
3-month follow-up phases. TRF-budesonide (16 mg/day [n=48]; 8 mg/day [n=51]) was 36 
compared with placebo (n=50) in patients with persistent proteinuria despite optimised 37 
renin-angiotensin system (RAS) blockade. Endpoints included mean change from baseline in 38 
urine protein creatinine ratio (UPCR) at 9 months (primary) and change in estimated 39 
glomerular filtration rate (eGFR). ClinicalTrials.gov number NCT01738035. 40 
Findings 41 
At 9 months, mean UPCR had decreased by -24·4% with TRF-budesonide (-27·3% with 42 
16 mg/day [p=0·0092], non-significant -21·5% with 8 mg/day [p=0·0290]), relative to +2·7% 43 
with placebo. The effect was sustained throughout follow-up; mean UPCR decreased by -44 
32·0% from baseline at 12 months for 16 mg/day vs. +0·5% for placebo. Over 9 months, 45 
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eGFR was stable with TRF-budesonide but decreased -9·8% with placebo (TRF-budesonide 46 
vs. placebo: p=0·0010). There were dose-dependent trends in the incidence of solicited 47 
corticosteroid-related adverse events and discontinuations, although the incidence of all 48 
adverse events was 87·8%, 94·1%, and 84·0% with 16 mg/day, 8 mg/day, and placebo, 49 
respectively. Two of 13 serious adverse events were possibly related to TRF-budesonide: 50 
deep vein thrombosis (16 mg/day) and unexplained deterioration in renal function in follow-51 
up. 52 
Interpretation 53 
TRF-budesonide, additional to optimised RAS blockade, reduced proteinuria and maintained 54 
eGFR in IgAN patients. Both these effects are indicative of a reduced risk of future 55 
progression to ESRD. These results suggest that TRF-budesonide has potential to become the 56 
first IgAN-specific treatment targeting intestinal mucosal immunity upstream of disease 57 
manifestation.  58 
Funding 59 
Pharmalink AB   60 
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Introduction 61 
Primary immunoglobulin A (IgA) nephropathy (IgAN) is the most prevalent chronic 62 
glomerular disease worldwide, with patients often diagnosed as young adults.1 63 
Approximately 20–40% of patients progress to end-stage renal disease (ESRD) within 10–64 
20 years of diagnosis.2–4 Major risk factors for progression to ESRD are persistent 65 
proteinuria, hypertension, and reduced glomerular filtration rate (GFR).1,3,5,6 KDIGO 66 
guidelines for glomerulonephritis recommend renin-angiotensin system (RAS) blockade 67 
utilizing angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin receptor blockers 68 
(ARBs) as first-line treatment for IgAN patients with proteinuria >1 g/day (recommendation 69 
level 1B), and suggest up-titration as far as tolerated up to the maximum recommended dose 70 
to achieve proteinuria <1 g/day (recommendation level 2D).7 For patients with persistent 71 
proteinuria >1 g/day and GFR >50 mL/min/1·73 m2 despite 6 months’ optimised RAS 72 
blockade, KDIGO suggest 6 months’ treatment with high-dose systemic corticosteroids 73 
(recommendation level 2C).7 However, use of high-dose systemic corticosteroids is 74 
associated with increased risks of adverse events and sequelae including serious infections, 75 
hypertension, weight gain, diabetes, and osteoporosis.8–10 The benefit of systemic 76 
immunosuppression, in addition to the intervention of dietary restrictions and polypharmacy 77 
upon optimised RAS blockade has recently been questioned in the STOP-IgAN trial.11 78 
Notwithstanding, there is an unmet need for a targeted treatment with a favourable 79 
risk-benefit profile in IgAN patients at risk of progression to ESRD.  80 
Evidence suggests a role for the mucosal immune system in the pathogenesis of IgAN.1,12,13 81 
In IgAN patients, mucosal B lymphocytes located in Peyer’s patches are thought to be primed 82 
to produce IgA1 that is galactose deficient (Gd-IgA1), which in the circulation can form large 83 
immune complexes with anti-glycan IgG antibodies.1,14–16 These complexes may bind to 84 
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glomerular mesangial cells and stimulate cell proliferation, release of inflammatory mediators 85 
that promote proteinuria, and fibrotic remodelling, ultimately leading to loss of renal 86 
function.1,15 This pathogenesis suggests that local immunosuppression of mucosal B 87 
lymphocyte activation and proliferation in Peyer’s patches could attenuate Gd-IgA1 88 
production,17 thereby reducing subsequent pathophysiological changes, assessed as a 89 
reduction in protein excretion by the kidneys.  90 
A novel, oral, targeted-release formulation of the glucocorticosteroid budesonide 91 
(TRF-budesonide; NEFECON™ [Pharmalink AB, Stockholm, Sweden]) was developed to 92 
release drug in the distal ileum, where Peyer’s patches reside at high density. The safety 93 
profile of TRF-budesonide was anticipated to be superior to high-dose systemic 94 
corticosteroids because of its extensive first pass metabolism: less than 10% of budesonide 95 
enters systemic circulation.18 In a previous exploratory phase 2a trial, 16 IgAN patients 96 
received TRF-budesonide (8 mg/day). Treatment over 6 months resulted in a statistically 97 
significant reduction in proteinuria and was well-tolerated.19 The objective of the current 98 
phase 2b trial was to evaluate the efficacy and safety of two doses of TRF-budesonide in 99 
IgAN patients at risk of progressing to ESRD due to persistent proteinuria despite optimised 100 
RAS blockade therapy.  101 
  102 
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Methods 103 
Trial design 104 
The NEFIGAN trial was randomised, double-blinded, and placebo-controlled in patients with 105 
biopsy-confirmed primary IgAN and overt proteinuria considered at risk of progressing to 106 
ESRD. This phase 2b trial was conducted at 62 sites across 10 European countries (Belgium, 107 
Czech Republic, Denmark, Finland, Germany, Italy, Spain, Sweden, The Netherlands, UK; 108 
see the Supplementary Appendix). Concerned competent authorities and ethics committees 109 
for participating centres approved the trial, which was conducted from December 2012 to 110 
June 2015 in accordance with Good Clinical Practice and the Declaration of Helsinki, 2008. 111 
Patients 112 
Male and female patients aged ≥18 years with biopsy-confirmed primary IgAN and overt 113 
proteinuria were eligible for the run-in phase. All patients provided written informed consent 114 
prior to enrolment. Inclusion criteria for randomisation to treatment included 115 
eGFR ≥45 mL/min/1·73 m2 and a urine protein creatinine ratio (UPCR) ≥0·5 g/g or urinary 116 
total protein ≥0·75 g/day, levels considered to increase risk of progressing to ESRD.20 The 117 
approach of using either 24 hour protein excretion or UPCR to determine eligibility was 118 
applied to overcome collection errors and deviations from normal creatinine excretion (eg 119 
physically active and muscular males), respectively, thus minimizingthe risk of unintentional 120 
exclusion of patients. Eligibility criteria are presented in Table S1.  121 
Procedures 122 
Trial medication was an oral capsule formulation of TRF-budesonide (NEFECON™; 123 
Pharmalink AB, Stockholm, Sweden) or placebo, designed to provide sustained release of 124 
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active compound that was delayed until the capsule reached the distal ileum,21 targeting 125 
where Peyer’s patches reside at high density.  126 
After screening, eligible patients were enrolled into a 6-month run-in phase, a 9-month 127 
treatment phase, and a 3-month follow-up phase; patient eligibility was assessed prior to 128 
run-in and treatment phases. During run-in, RAS blockade was optimised by up-titrating 129 
ACEIs and/or ARBs to a maximum recommended or tolerated dose, to a target blood 130 
pressure <130/80 mmHg, UPCR <0·5 g/g, and urine protein <0·75 g/day. At the end of 131 
run-in, patients with persistent proteinuria (UPCR ≥0·5 g/g or proteinuria ≥0·75 g/day) 132 
despite optimised RAS blockade, estimated GFR (eGFR [CKD-EPI serum creatinine 133 
equation22]) or measured GFR ≥45 mL/min/1·73 m2, and blood pressure ≤160/100 mmHg 134 
were eligible for randomisation to treatment. Run-in phase directives are detailed in the 135 
Supplementary Appendix. 136 
An independent Data and Safety Monitoring Board (DSMB) monitored all safety issues and 137 
reviewed data at interim analysis. 138 
Randomisation and masking 139 
Patients were stratified according to baseline UPCR (≤0·9 g/g and >0·9 g/g) at Month 0 140 
(baseline). Allocation of patients to treatment groups was done by randomisation using the 141 
method of randomly permuted blocks. Within each block, patients were allocated in a 1:1:1 142 
ratio to TRF-budesonide 16 mg/day, 8 mg/day, or placebo. All patients continued optimised 143 
RAS blockade treatment throughout the trial. Randomisation was performed by Pharma 144 
Consulting Group AB, Uppsala, Sweden. 145 
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The trial was double-blind and the allocation to treatment groups was, therefore, unknown to 146 
the patient, the investigator, the sponsor, or the monitor. The sponsor and investigators were 147 
fully blinded to randomised treatment assignment and the pre-planned interim analysis.  148 
To ensure blinding, placebo capsules were used with the same appearance and route of 149 
administration as the active capsules. Patients self-administered blinded capsules, once daily, 150 
1 hour before breakfast during the treatment phase. During follow-up (Months 9–12), patients 151 
who received TRF-budesonide 16 mg/day during Months 0–9 were tapered to 8 mg/day for 152 
2 weeks while all other patients (ie, those who received TRF-budesonide 8 mg/day or placebo 153 
during Months 0–9) received placebo to maintain blinding. No further trial medication was 154 
administered after tapering. 155 
Treatment code envelopes were provided for each randomised patient. In case of emergency, 156 
the code envelope could be opened. Any unblinded patient had to be withdrawn from the 157 
trial. 158 
Outcomes 159 
The primary outcome was mean change from baseline in UPCR over the 9-month treatment 160 
phase. The primary analysis compared mean change from baseline in UPCR at 9 months 161 
between TRF-budesonide-treated patients (16 mg/day and 8 mg/day combined) and 162 
placebo-treated patients.  163 
Key secondary and tertiary outcomes, assessed at various time points, included mean changes 164 
from baseline in eGFR; UPCR, 24-hour urine protein, urine albumin creatinine ratio 165 
(UACR), and 24-hour urine albumin were calculated from measured 24-hour urine samples; 166 
the presence or absence of microhaematuria, assessed by dipstick. 167 
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Standardised questionnaires were used at each visit to ask patients about the presence of 168 
specific gastrointestinal-related and corticosteroid-related adverse events. All solicited and 169 
spontaneously-reported adverse events were recorded from screening until the end of trial, 170 
and coded using the Medical Dictionary for Regulatory Activities (Version 16·0E). Vital 171 
signs, clinical chemistry, and haematology parameters were assessed.  172 
Statistical analysis 173 
Individual patient data from other relevant studies were used to estimate UPCR variability 174 
and the expected change from baseline at 9 months for placebo.23,24  The geometric mean 175 
ratio of 9 month:baseline UPCR values was 0·88 (log standard deviation [SD]: 0·597). The 176 
corresponding geometric mean ratio for TRF-budesonide was estimated from a previous 177 
exploratory phase 2a trial19 as 0·60 (log SD: 0·488). Sample size calculations were based on 178 
the hypothesis that the true difference between TRF-budesonide (16 mg/day and 8 mg/day 179 
combined) and placebo in log UPCR change from baseline was log(0·60) - log(0·88) 180 
corresponding to an absolute difference of (1-0·6) - (1-0·88) = 28%. A trial with 150 patients 181 
(50 per treatment arm) provided more than 90% power to detect this level of treatment effect 182 
for TRF-budesonide (16 mg/day and 8 mg/day combined) vs. placebo at the one-sided 2.5% 183 
alpha level.  184 
The primary outcome (mean change from baseline in UPCR over the 9-month treatment 185 
phase) was assessed on the full analysis set (FAS), defined as all randomised patients who 186 
took at least one dose of trial medication and had at least one post-dose efficacy measurement 187 
(modified intention-to-treat analysis). A formal interim analysis governed by the DSMB was 188 
prospectively planned for when 90 patients completed 9 months’ treatment, while the other 189 
patients in the FAS had entered the study but had not reached 9 months. Thus data from all 190 
randomised patients in the FAS, regardless of whether they had reach 9 months, was included 191 
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in the interim analysis, which was analysed using a mixed model repeated measures 192 
(MMRM) model. The threshold for significance for TRF-budesonide (16 mg/day and 193 
8 mg/day) vs. placebo on the primary outcome was 1·58% one-sided; futility could also be 194 
declared if predictive power was ≤5%. The alpha level applied at final analysis was 1·52% 195 
one-sided to ensure an overall Type I error rate of 2·5% one-sided. 196 
It was prospectively planned that if statistical significance for the primary outcome was met 197 
during the interim analysis: (a) the trial would continue; and (b) that during the final analysis 198 
(after all patients had completed the trial), confirmation of the interim analysis result would 199 
be gained by analysing the mean change from baseline in UPCR over the 9-month treatment 200 
and 3-month follow-up phases.  201 
All secondary and tertiary endpoints were analysed during the final analysis. It was 202 
prospectively planned that all secondary and tertiary comparisons between treatment groups 203 
could only be made if statistical significance for the primary outcome was met during the 204 
interim analysis. 205 
The following post-hoc analysis was defined after the interim analysis, and before the final 206 
database lock: The treatment effects on UPCR and eGFR CKD-EPI as a function of baseline 207 
UPCR and eGFR. 208 
All efficacy data were analysed using MMRM analysis with fixed effect terms for baseline 209 
log UPCR, randomised treatment group, UPCR stratification level, visit, and visit by 210 
treatment group interaction. Subject and region were included as random effects. Region was 211 
defined on the country level, although Denmark was combined with Sweden (region = 212 
Scandinavia) and Belgium with the Netherlands (region = Benelux) due to small patient 213 
numbers per country. 214 
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Statistical analyses were performed by Scandinavian Development Services AB, Sweden, 215 
using SAS® (Version 9·3). 216 
This trial is registered with ClinicalTrials.gov, number NCT01738035. 217 
Role of the funding source 218 
The funder oversaw all study processes. Alex Mercer is an employee of the funder, who 219 
participated in data analysis, data interpretation, and writing of the report. Both placebo and 220 
TRF-budesonide treatments were provided by the funder. Data collection was performed by 221 
Crown CRO Oy and Pharma Consulting Group AB. Statistical analysis was performed by 222 
Scandinavian Development Services AB. Dr Kevin Carroll of KJC Statistics Ltd provided 223 
statistical input and medical writing. Dr. Heather Cook of PharmaLogic Consulting AB 224 
contributed to the study design, submissions for approval to concerned regulatory agencies, 225 
data interpretation and writing of the report. Dr Ellen Robertshaw and Dr Justin Cook of 226 
Niche Science and Technology Ltd and Dr Michael Riley of Trilogy Writing and Consulting 227 
GmbH provided medical writing services, financed by the sponsor Pharmalink AB. 228 
Following database lock and unblinding, the sponsor and all investigators had access to 229 
analyses performed on trial data. The corresponding author was responsible for submitting 230 
the manuscript for publication.  231 
12 
 
Results 232 
In total, 297 patients were screened between December 11, 2012, and December 26, 2013, 233 
and 207 patients were enrolled into the run-in phase. Following run-in, all patients eligible for 234 
randomisation to treatment were receiving either a maximum tolerated or maximum 235 
recommended dose of ACEIs and/or ARBs. A total of 150 randomised patients received 236 
blinded trial medication; 149 comprised the FAS (one patient was unable to swallow 237 
capsules) (Figure 1 and Table S2). Trial drug exposure is described in the Supplementary 238 
Appendix. Treatment groups (TRF-budesonide 16 mg/day, 8 mg/day, and placebo) were 239 
well-balanced regarding demographic and baseline characteristics, with all patients using 240 
RAS blockade therapy (Table 1). Patients maintained optimised RAS blockade treatment 241 
throughout the trial. In a minority of patients, changes in dose or drug were made in RAS 242 
blockade (17 [11·3%] patients]) or diuretics (10 [6·7%] patients]). The frequencies of 243 
changes were comparable across the TRF-budesonide and placebo treatment groups (Table 244 
S3).  245 
In the pre-planned interim analysis shown in Figure 2A, the primary outcome of geometric 246 
LS mean UPCR at 9 months was reduced from baseline by 24·4% (absolute change in UPCR 247 
to be presented) in all TRF-budesonide-treated patients combined versus an increase of 2·7% 248 
(absolute change in UPCR to be presented) in placebo-treated patients and the difference was 249 
statistically significant (p=0·0066) (Figure 2A; Note: all point estimates and 95% CIs in the 250 
following are presented in Table S4). Hence, the primary objective of the trial was met and 251 
the corresponding null hypotheses rejected. Geometric LS mean changes from baseline 252 
were -27·3% for TRF-budesonide 16 mg/day and -21·5% for 8 mg/day. The difference in 253 
UPCR at 9 months was statistically significant for TRF-budesonide 16 mg/day vs. placebo 254 
(p=0·0092), but not 8 mg/day vs. placebo (p=0·0290), which did not meet the adjusted p-255 
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value at interim analysis (p≤0·0158). Change in UPCR from baseline at 9 months in the final 256 
analysis was consistent with the change in the interim analysis (Figure 2A) and is presented 257 
as absolute mean change in UPCR from baseline across the 12 months of the randomized 258 
portion of the study (Figure 2B).  259 
In addition to the interim analysis performed when 90 patients had completed  9 months’ 260 
treatment, a final analysis was also performed when all patients had completed the trial. In 261 
this final analysis, when assessed as a secondary outcome, reduction in UPCR at 9 months vs. 262 
baseline showed TRF-budesonide had a consistent effect on the relative change in UPCR 263 
regardless of baseline UPCR levels (Figure S1). Upon completion of the 3-month follow-up, 264 
the geometric LS mean reduction in UPCR was sustained in the TRF-budesonide 8 mg/day 265 
group (-22·6% change versus baseline) and continued to decrease in the 16 mg/day group 266 
(-32·0% change versus baseline) vs. an increase of 0·5% for placebo. Compared to placebo, 267 
the changes for both active treatment groups were statistically significant (16 mg/day vs. 268 
placebo, p=0.0005; 8 mg/day vs. placebo, p=0·010). Changes in 24-hour protein excretion, 269 
UACR, and 24-hour albumin excretion were consistent with the UPCR data (data not shown). 270 
eGFR remained stable in the TRF-budesonide groups but decreased in the placebo-treated 271 
group during the treatment phase in the final analysis, as shown by percent changes at 272 
9 months (Figure 3A) and by absolute mean changes in eGFR from baseline across the 12 273 
months (Figure 3B). Mean percent change from baseline in eGFR at 9 months was -9·8% for 274 
placebo, +0·6% for 16 mg/day, and -0·9% for 8 mg/day (Figure 3A). Comparisons with 275 
placebo achieved statistical significance at 9 months (16 mg/day vs. placebo: p=0·0026; 276 
8 mg/day vs. placebo: p=0·0064). Exploratory post-hoc analyses suggested that stabilisation 277 
of eGFR in TRF-budesonide-treated groups was independent of baseline UPCR and eGFR 278 
values, and that the degree of eGFR reduction in the placebo group appeared related to the 279 
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magnitude of baseline UPCR (Figure S1). eGFR levels in the TRF-budesonide 16 mg/day 280 
group were sustained throughout the trial (mean percent change from baseline at 281 
12 months: -0·7vs. -10·9% for placebo; p=0·0134). 282 
When assessed as a tertiary outcome in the final analysis, the proportion of patients with 283 
microhaematuria in the TRF-budesonide 16 mg/day group decreased from 87·5% (n=42 of 284 
48) at baseline to 43·8% (n=21 of 48) at 9 months, and was statistically significant versus 285 
placebo (74·0% [n=37 of 50] of placebo-treated at 9 months, 95%CI 0.072-0.675, OR 0.221, 286 
p=0·0041) but remained unchanged in the 8 mg/day-and placebo-treated groups.  287 
There were no deaths and no patient progressed to ESRD. Fourteen patients 288 
(TRF-budesonide 16 mg/day, n=3; 8 mg/day, n=4; placebo, n=7) reported 289 
treatment-emergent adverse events associated with worsening of renal function and/or 290 
received high-dose systemic corticosteroid therapy.  291 
Eleven patients reported 13 treatment-emergent serious adverse events (Table S5). Two were 292 
considered possibly related to TRF-budesonide by investigators blinded to study treatment: 293 
deep vein thrombosis (16 mg/day), and unexplained worsening of renal function, reported 294 
during follow-up after tapering from 16 mg/day to 8 mg/day. Two serious adverse events in 295 
the placebo-treated group were considered possibly related to trial medication: both cases of 296 
increased proteinuria, one with a decline in renal function (see the Supplementary Appendix 297 
for details on adverse event reporting). 298 
The total incidence of treatment-emergent adverse events was similar across treatment groups 299 
(Table 2). The most frequently reported adverse event, nasopharyngitis, was reported by 300 
similar percentages of patients in each group. There were no statistically significant changes 301 
from baseline in body weight, blood pressure, or glycated haemoglobin A1 (HbA1c) values in 302 
either TRF-budesonide group vs. placebo at end of treatment (Table S6, post-hoc analysis). 303 
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Two patients receiving TRF-budesonide, both with a body mass index of 36 kg/m2 at 304 
baseline, exhibited increases in HbA1c into the diabetic range (≥48 mmol/mol) at the end of 305 
treatment or during follow-up (Table S6 footnote for details). There were no other clinically 306 
relevant changes in clinical chemistry variables in any treatment group (see the adverse event 307 
reporting section of the Supplementary Appendix for the list of clinical chemistry variables 308 
investigated). The incidence of gastrointestinal-related adverse events was similar in 309 
TRF-budesonide-treated and placebo-treated patients (Table S7). 310 
Solicited corticosteroid-related adverse events were more frequently reported by 311 
TRF-budesonide-treated patients (Table S8). Eighteen patients experienced adverse events 312 
that led to discontinuation of treatment (n=11 in the 16 mg/day group, n=5 in the 8 mg/day 313 
group, n=2 in the placebo group). The majority of patients who discontinued in the 314 
TRF-budesonide groups experienced corticosteroid-related adverse events (Table S9).   315 
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Discussion 316 
We report the results of the NEFIGAN trial in which 9 months’ treatment with 317 
TRF-budesonide resulted in a statistically significant reduction in UPCR vs. placebo in 318 
patients with primary IgAN. This primary outcome was met in a pre-specified interim 319 
analysis of data from the FAS population. The effect of TRF-budesonide was shown to be 320 
dose- and time-dependent. Upon completion of the 3 month follow up, the mean percent 321 
reduction in UPCR was sustained in the TRF budesonide 8 mg/day group and continued to 322 
decrease in the 16 mg/day group. This persistence of effect following cessation of treatment 323 
is suggestive of a disease-modifying effect. There is a growing body of evidence and general 324 
acceptance that a reduction in proteinuria is associated with a reduced risk of ESRD in IgAN 325 
patients, and time-averaged (TA)-proteinuria is predictive of renal survival in IgAN patients: 326 
the rate of decline of renal function and subsequent risk of renal failure are associated with 327 
higher levels of TA-proteinuria.5,20 A recent meta-analysis of IgAN trials used contemporary 328 
statistical methodology to assess the possible surrogacy of the effect of treatment intervention 329 
(RAS blockade, fish oil, immunosuppression, and steroids) on proteinuria at 9 months to 330 
predict the effect of the intervention on ESRD clinical outcome. The analysis showed a 331 
statistically significant association, suggesting that an improvement in proteinuria at 9 months 332 
for drug compared to control would be positively associated with an improvement in longer 333 
term ESRD outcome.25  334 
Patients entering the treatment phase of this trial were at risk of progression to ESRD due to 335 
persistent proteinuria despite optimised RAS blockade. The further reduction in proteinuria 336 
was achieved by targeting an alternative pharmacological mechanism, and was attributable to 337 
TRF-budesonide, irrespective of baseline UPCR, eGFR and time since diagnosis of IgAN ( 338 
Fig S1D). Our findings support the generally accepted hypothesis that mucosal immune 339 
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system dysfunction has a significant role in the pathogenesis of IgAN, as TRF-budesonide 340 
targets the region of the gastrointestinal tract where Peyer’s patches reside at high density.  341 
eGFR declined in the placebo-treated group but remained stable in the TRF-budesonide 342 
groups following 9 months’ treatment, an effect that persisted throughout follow-up in the 16 343 
mg/day group. Stabilisation of eGFR in IgAN patients is likely to predict a favourable 344 
outcome. It should be noted that RAS blockade therapy remained optimised throughout the 345 
trial, with no dose changes during the treatment phase, except in a small number of 346 
individuals (dose of RAS blockade was increased for 5/150 patients and decreased for 6/150 347 
patients), distributed across the 3 treatment groups (see Table S3). Despite the rigorous 348 
maintenance of RAS blockade, the rapid rate of loss of eGFR observed in the placebo-treated 349 
group was greater than that seen in the recently reported STOP-IGAN study11 but consistent 350 
with other studies of IgAN in patients receiving optimised RAS blockade, albeit with 351 
generally higher levels of baseline proteinuria.24,26 Of note, posthoc analysis demonstrated 352 
that eGFR reduction in the placebo group was  related to  baseline proteinuria (Fig S1B), ( 353 
but not to baseline  blood pressure ? (not shown) ?Is this correct ? I did not see any 354 
stat.analysis on that ? ) As histology data are not available for all of these studies, it is 355 
difficult to speculate on the contribution of histopathological changes to rate of eGFR 356 
decline. However, the deterioration in eGFR illustrates that this patient population is at risk of 357 
disease progression, current standard-of-care therapy is insufficient, and there is a need for 358 
further intervention in IgAN patients with persistent proteinuria.  359 
High-dose systemic corticosteroids and other potent immunosuppressive treatments have 360 
been studied in a number of randomised controlled trials with varying results.27 A 361 
consequence of these trials has been the necessity to test interventions with a background of 362 
optimised standard-of-care RAS blockade, as has been conducted in this trial. This has also 363 
been applied in the TESTING trial, a randomised controlled trial evaluating high-dose 364 
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systemic corticosteroid therapy vs. placebo (recruitment was stopped early and randomised 365 
treatment discontinued due to safety concerns, interim results published)32, and in the STOP-366 
IgAN trial.11 The STOP-IgAN trial assessed the potential benefit of systemic 367 
immunosuppression in addition to the intervention of dietary restrictions and polypharmacy 368 
upon optimised RAS blockade, and is the first study in IgAN to employ such comprehensive 369 
supportive care. No difference in the rate of decrease in eGFR was observed between groups 370 
over the 3-year period of the STOP-IgAN trial.11 The slow annual loss of eGFR in the 371 
intensive supportive care group (1·6 mL/min/1·73 m2) suggests that further interventions, in 372 
addition to optimised RAS blockade, retards the loss of renal function.11 373 
TRF-budesonide 16 mg/day resulted in a statistically significant reduction in the presence of 374 
microhaematuria at 9 months vs. placebo. Although the prognostic significance of haematuria 375 
disappearance in IgAN has not been prospectively investigated, clinical and experimental 376 
studies suggest that haematuria is associated with glomerular and tubulointerstitial damage in 377 
IgAN and other glomerular diseases.28,29 378 
In the present trial, TRF-budesonide appeared to be safe and generally well-tolerated, 379 
although there was a dose-dependent trend in the incidence of solicited corticosteroid-related 380 
adverse events and in discontinuations due to these events (see Tables S8 and S9). 381 
Budesonide, administered as a targeted-release oral dosage form, is subject to high first-pass 382 
metabolism, resulting in low systemic exposure (approximately 10% of administered dose).18 383 
Some degree of systemic exposure is reflected in reduced cortisol excretion (data not shown) 384 
and the aforementioned dose-dependent trend in the incidence of solicited 385 
corticosteroid-related adverse events. However, several studies have reported higher 386 
incidences of diabetes mellitus or impaired glucose tolerance, hypertension, and weight gain 387 
in high-dose systemic corticosteroid-treated patients.11,30 Furthermore, increased incidences 388 
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of serious and fatal infections were documented with high-dose systemic immunosuppressive 389 
therapy in the STOP-IgAN trial11 and TESTING trial32. In contrast, no serious infections 390 
were attributed to TRF-budesonide in the NEFIGAN trial and there were no statistically 391 
significant changes in blood pressure, HbA1c, or body weight with TRF-budesonide vs. 392 
placebo. There was a trend for numerically higher systolic and diastolic blood pressure levels 393 
in the TRF-budesonide 16 mg group at the end of treatment compared to baseline values, but 394 
this was not statistically significant (Table S6). The NEFIGAN trial data indicate that 395 
TRF-budesonide may elicit fewer and less severe systemic effects and has a preferable 396 
tolerability profile than previously reported for high-dose systemic corticosteroid regimens, 397 
when used to treat IgAN patients at risk of progression to ESRD, many of whom are young 398 
adults.11,30  However, this needs to be confirmed in larger studies than the current phase 2b 399 
trial. 400 
Proteinuria is a major risk factor for renal failure in IgAN.3,5 As addressed by Rauen et al.,11 401 
in the past, clinically significant proteinuria has been arbitrarily defined as an excretion level 402 
greater than 1 g/day (KDIGO guidelines).7 However, evidence from epidemiology studies 403 
indicate that IgAN patients with proteinuria of 0·5 to 1 g/day are at increased risk of renal 404 
failure.20,31 Thus, to evaluate TRF-budesonide in a clinically relevant high-risk IgAN 405 
population, a proteinuria threshold of either 0·75 g/day or 0·5 g/g UPCR (on a 24-hour 406 
collection) was selected. A threshold level of 0·75 g/day was similarly applied in the recently 407 
reported STOP-IgAN trial. 408 
The primary objective of this trial was to assess the effect of TRF-budesonide on UPCR, a 409 
proteinuria-based measure and surrogate endpoint for renal failure. While both a reduction in 410 
UPCR and stabilisation of eGFR were demonstrated, it will be necessary to quantify the 411 
magnitude of relative risk reduction associated with TRF-budesonide-treatment in IgAN 412 
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patients at risk of progression to ESRD in a larger trial of longer duration. Another limitation 413 
of the present trial is that the patient population treated was almost exclusively Caucasian. In 414 
addition, allowing entry of patients in to the study regardless of time since biopsy, led to a 415 
lack of availability of recent histopathology data on all patients prior to randomization 416 
prevented the implementation of a stratification strategy to discount imbalance of renal 417 
histology score as a potential confounder. However, in a post-hoc analysis, a consistent effect 418 
on relative change in UPCR at 9 months was observed regardless of time from diagnosis 419 
(Figure S1d) indicating that this did not affect the results. There are also no published 420 
pharmacokinetic data for TRF-budesonide in patients with IgAN. Patients with severe hepatic 421 
impairment were excluded from the study but it is unknown if IgAN patients may be subject 422 
to higher systemic exposure due to increased mucosal GI absorption. There is evidence of 423 
increased exposure of budesonide in chronic inflammatory bowel disease (range 11-21% 424 
vs.9-12% in healthy volunteers) but that systemic exposure normalises after 8 weeks of 425 
treatment33. Nevertheless, this trial is one of the largest randomised controlled trials 426 
conducted in IgAN in which RAS blockade was optimised prior to adjunct therapy. 427 
This trial demonstrated that 9 months’ treatment with TRF-budesonide resulted in reduced 428 
proteinuria and stabilised eGFR in IgAN patients at risk of progression to ESRD. The 429 
observed effect was additive to optimised RAS blockade and supports the use of 430 
TRF-budesonide as adjunct therapy in IgAN patients with persistent proteinuria. 431 
TRF-budesonide has the potential to become the first disease-specific treatment for IgAN, 432 
with a risk-benefit profile supportive of its use early in the course of disease. 433 
Research in context 434 
Evidence before this trial 435 
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We searched PubMed up to April 26, 2016, for published papers about NEFECON using the 436 
following search terms (with no language restrictions): “targeted-release”, “budesonide”, 437 
“TRF-budesonide”, and “NEFECON”. We identified one relevant paper. In 2011, Smerud 438 
and colleagues19 reported an open-label, uncontrolled, exploratory phase 2a trial, in which 16 439 
IgAN patients received TRF-budesonide. Treatment over 6 months resulted in a statistically 440 
significant reduction in proteinuria and was well tolerated.19  441 
Added value of this trial 442 
To date, the current phase 2b trial is the only randomised, double-blinded, placebo-controlled 443 
trial to investigate and demonstrate that TRF-budesonide, additional to optimised RAS 444 
blockade, reduced proteinuria and stabilised eGFR in IgAN patients at risk of progression to 445 
ESRD. At 9 months, mean UPCR had decreased by 24·4% in all TRF budesonide-treated 446 
patients combined versus an increase of 2·7% in placebo-treated patients (combined TRF 447 
budesonide vs. placebo: p=0·0066). The effect was sustained throughout follow-up for 448 
16 mg/day; mean UPCR decreased 32·0% from baseline at 12 months vs. 0·5% for placebo. 449 
Over 9 months, eGFR was stable with TRF-budesonide but decreased 9·8% with placebo 450 
(combined TRF-budesonide vs. placebo:, p=0·0010). Both these effects are indicative of a 451 
reduced risk of future progression to ESRD.  452 
Implications of all the available evidence 453 
TRF-budesonide has the potential to become the first IgAN-specific treatment targeting 454 
intestinal mucosal immunity upstream of disease manifestation, reducing the risk of 455 
progression to ESRD.  456 
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Table 1: Patient demographics and baseline characteristics* (full analysis set) 
Variable  
Placebo 
(N=50) 
TRF-budesonide 
8 mg/day 
(N=51) 
TRF-budesonide 
16 mg/day 
(N=48) 
Total 
(N=149) 
Age (years)  38·9 (12·0) 40·6 (13·0) 37·5 (11.9) 39·0 (12·3) 
Sex, n (%) Male 35 (70·0) 37 (72·5) 33 (68·8) 105 (70·5) 
BMI (kg/m2) 27·5 (5·37) 26·5 (4·39) 27·8 (5·17) 27·3 (4·99) 
Weight (kg) 85·2 (18·89) 80·9 (14·46) 86·7 (16·89) 84·2 (16·89) 
Race, n (%) Asian 1 (2·0) 0 1 (2·1) 2 (1·3) 
 Caucasian 48 (96·0) 49 (96·1) 47 (97·9) 144 (96·6) 
 Other 1 (2·0) 2 (3·9) 0 3 (2·0) 
Ethnicity, n (%) Hispanic/Latino 3 (6·0) 11 (21·6) 7 (14·6) 21 (14·1) 
 Non-Hispanic/Non-Latino 47 (94·0) 40 (78·4) 41 (85·4) 128 (85·9) 
Blood pressure (mmHg) Systolic 128·1 (11·87) 127·7 (13·56) 126·7 (11·62) 127·5 (12·33) 
 Diastolic 80·2 (10·13) 80·3 (9·66) 78·1 (9·59) 79·6 (9·78) 
UPCR (g/g), median (range) 0·83 (0·33–4·12) 0·81 (0·26–3·00) 0·79 (0·22–2·10) 0·81 (0·22–4·12) 
24-hour protein (g/day), median (range) 1·23 (0·57–9·75) 1·14 (0·44–3·31) 1·32 (0·41–10·66) 1·2 (0·41–10·66) 
eGFR CKD-EPI (creatinine formula) (mL/min/1·73 m2) 76·5 (23·2) 74·1 (25·8) 83·8 (25·9) 78·3 (25·1) 
Patients with microhaematuria, n (%) 40 (80·0) 32 (62·7) 42 (87·5) 114 (76·5) 
Time from diagnosis to start of treatment (days), median (range) 1101 (202-8153) 1972 (209-7833) 1218.5 (186-11048) 1499 (186-11048) 
Patients previously treated with corticosteroids/immunosuppressants, n (%) 7 (14·0) 14 (27·5) 6 (12·5) 27 (18·1) 
Patients on ACEI alone, n (%) [% on maximum recommended dose] 21 (42·0) [28·0] 25 (49·0) [21·6] 26 (52·4) [29·2] 72 (48·3) [26·2] 
Patients on ARB alone, n (%) [% on maximum recommended dose] 16 (32·0) [20·0] 14 (27·5) [15·7] 14 (29·2) [18·8] 44 (29·5) [18·1] 
Patients on ACEI and ARB, n (%) [% on maximum recommended dose] 13 (26·0) [6·0] 12 (23·5) [3·9] 8 (16·7) [4·2] 33 (22·1) [4·7] 
Patients who made lifestyle changes during the run-in phase, n (%)† 16 (32·0) 18 (35·3) 14 (29·2) 48 (32·2) 
*Unless otherwise indicated, values are expressed as mean (standard deviation). 
†Including salt intake, fluid intake, protein intake, fish oil intake, smoking, exercise. 
ACEI=angiotensin-converting-enzyme inhibitor. ARB=angiotensin receptor blocker. BMI=body mass index. CKD-EPI=chronic kidney disease 
epidemiology collaboration equation. UPCR=urine protein creatinine ratio. 
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Table 2: Treatment-emergent adverse events reported by ≥5% of all patients by preferred term (safety set)* 
Preferred Term 
Placebo 
(N=50) 
TRF-budesonide 
8 mg/day 
(N=51) 
TRF-budesonide 
16 mg/day 
(N=49) 
Total 
(N=150) 
n (%) e n (%) e n (%) e n (%) e 
Any AE 42 (84) 162 48 (94) 270 43 (88) 305 133 (88) 737 
Nasopharyngitis 10 (20) 14 8 (16) 16 10 (20) 16 28 (19) 46 
Acne‡ 3 (6) 3 8 (16) 9 9 (18) 10 20 (13) 22 
Joint swelling 2 (4) 2 8 (16) 8 9 (18) 14 19 (13) 24 
Cushingoid‡ 3 (6) 3 5 (10) 5 8 (16) 8 16 (11) 16 
Insomnia‡  2 (4) 2 6 (12) 6 8 (16) 9 16 (11) 17 
Diarrhoea  7 (14) 9 1 (2) 1 5 (10) 5 13 (9) 15 
Dyspepsia† 4 (8) 5 2 (4) 2 7 (14) 9 13 (9) 16 
Headache 3 (6) 4 3 (6) 3 6 (12) 6 12 (8) 13 
Alopecia‡ 2 (4) 2 4 (8) 5 4 (8) 4 10 (7) 11 
Back pain 1 (2) 1 6 (12) 8 3 (6) 3 10 (7) 12 
Mood swings‡ 2 (4) 2 3 (6) 3 5 (10) 5 10 (7) 10 
Oedema peripheral 2 (4) 3 2 (4) 3 6 (12) 9 10 (7) 15 
Blood creatine phosphokinase increased 3 (6) 3 3 (6) 4 3 (6) 3 9 (6) 10 
Hirsutism‡ 1 (2) 1 3 (6) 3 5 (10) 5 9 (6) 9 
Hypertension 1 (2) 1 3 (6) 3 5 (10) 5 9 (6) 9 
Muscle spasms 2 (4) 3 5 (10) 5 2 (4) 2 9 (6) 10 
Abdominal pain† 1 (2) 1 4 (8) 4 3 (6) 4 8 (5) 9 
Nausea 1 (2) 1 4 (8) 4 3 (6) 5 8 (5) 10 
Upper respiratory tract infection 3 (6) 3 2 (4) 3 3 (6) 3 8 (5) 9 
*Table displays adverse events reported by ≥5% of the total patient population. 
†Gastrointestinal-related adverse events solicited by questionnaire at every visit. 
‡Corticosteroid-related adverse events solicited by questionnaire at every visit. 
AE=adverse event. n=number of patients. e=number of events. 
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Figure 1: Patient CONSORT diagram 
Flow diagram of all patients screened, enrolled, and randomised with reasons for withdrawal. 
*FAS corresponds to the modified intention-to-treat analysis set. 
ACEI=angiotensin-converting enzyme inhibitors. AE=adverse event. ARBs=angiotensin 
receptor blockers. CTP=clinical trial protocol. FAS=full analysis set. SAE=serious adverse 
event. 
Figure 2: Change in UPCR from baseline 
Panel A shows the percent change in UPCR from baseline in patients after receiving placebo 
or TRF-budesonide (16 mg/day and 8 mg/day combined, 16 mg/day, and 8 mg/day) for 
9 months at the interim analysis (primary outcome). The comparisons of TRF-budesonide 16 
mg/day and 8 mg/day combined and 16 mg/day with placebo were statistically significant, 
but not 8 mg/day vs. placebo (p=0·0290). Panel B shows the absolute mean change in UPCR 
from baseline in patients receiving TRF-budesonide 16 mg/day, 8 mg/day, or placebo over 
the 9 month treatment phase (solid line) and 3 month follow-up phase (dashed line). 
UPCR=urine protein creatinine ratio. Data are expressed as mean±standard error of the mean. 
In both panels, the changes in UPCR are based on data from all 149 patients in the FAS. 
Figure 3: Change in eGFR from baseline  
Panel A shows the percent change in eGFR CKD-EPI from baseline in patients after 
receiving placebo or TRF-budesonide (16 mg/day and 8 mg/day combined, 16 mg/day, and 8 
mg/day) for 9 months. The comparisons of TRF-budesonide 16 mg/day and 8 mg/day 
combined, 16 mg/day, and 8 mg/day with placebo were statistically significant. Panel B 
shows the absolute mean change in eGFR CKD-EPI from baseline in patients receiving 
TRF-budesonide 16 mg/day, 8 mg/day or placebo over the 9 month treatment phase (solid 
line) and 3 month follow-up phase (dashed line). CKD-EPI=chronic kidney disease 
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epidemiology collaboration equation. eGFR=estimated glomerular filtration rate. Data are 
expressed as mean±standard error of the mean. In both panels, the changes in UPCR are 
based on data from all 149 patients in the FAS. 
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Figure 1  
 
Not randomised:
•Randomisation criteria not met (n=37)
•Withdrawal of consent (n=4)
•Immunosuppressive/corticosteroid treatment (n=3)
•Lost to follow-up/did not return to clinic (n=2)
•(S)AE (n=2)
•Pregnancy/ intention of becoming pregnant (n=1)
•Other (n=5)
TRF-budesonide 
16 mg/day, n=51
Received intervention, 
(safety set) n=51
Received intervention, 
(safety set) n=49
TRF-budesonide 
8 mg/day, n=51
Placebo, n=51
Intervention not received:
•Randomisation criteria not met 
(n=2)
FAS*, n=50 FAS*, n=51 FAS*, n=48
Received intervention, 
(safety set) n=50
Not enrolled:
•Screening failure (n=87)
•Withdrawal of consent (n=2)
•Not in patient’s interest (n=1)
Intervention not received:
•Randomisation criteria not met 
(n=1)
Completed trial as 
planned, n=46
Completed trial as 
planned, n=40
Completed trial as 
planned, n=34
207 enrolled into run-in
297 screened
153 randomised
Withdrawn:
•Inability to swallow tablets 
(n=1)
Discontinued trial medication:
•AE (n=2)
•Initiation of 
immunosuppressive/systemic 
corticosteroid treatment (n=1)
•Inability to tolerate 
ACEIs/ARBs (n=1)
Discontinued trial medication:
•(S)AE (n=11)
•Withdrawal of consent (n=1)
•Personal reasons  (n=1)
•Other (travelling distance) 
(n=1)
Discontinued trial medication:
•AE (n=5)
•Initiation of 
immunosuppressive/systemic 
corticosteroid treatment (n=1)
•CTP violation (n=4)
•Other (pregnancy/intention of 
becoming pregnant) (n=1)
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Figure 3 
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